IZOZF Stock Price & Financials - Izotropic Corporation
$0.17 (0.59%)| freeCashFlowPerShare | -0.011 |
| marketCap | 5,924,659.73 |
| peRatio | -3.795 |
| freeCashFlowYield | -0.1 |
| payoutRatio | 0 |
| roic | 0.875 |
| Price | 0.193 |
| VolAvg | 41,614 |
| MktCap | 11,655,163 |
| LastDiv | 0 |
| industry | Medical - Diagnostics & Research |
Income Statement Financials
Balance Statement Financials
Cash Flow Statement Financials
| 2023-04-30 | 2022-04-30 | 2022-04-30 | |
|---|---|---|---|
| fillingDate | 2023-04-30 | 2022-04-30 | 2022-04-30 |
| calendarYear | 2,023 | 2,022 | 2,021 |
| period | FY | FY | FY |
| cashAndCashEquivalents | 165,685 | 1,856,573 | 1,856,573 |
| shortTermInvestments | 28,750 | 0 | 0 |
| cashAndShortTermInvestments | 165,685 | 1,856,573 | 1,856,573 |
| netReceivables | 13,406 | 41,261 | 41,261 |
| inventory | 0 | 0 | 0 |
| otherCurrentAssets | 138,253 | 352,214 | 352,214 |
| totalCurrentAssets | 317,344 | 2,250,048 | 2,250,048 |
| propertyPlantEquipmentNet | 124,769 | 18,987 | 18,987 |
| goodwill | 0 | 0 | 0 |
| intangibleAssets | 0 | 0 | 0 |
| goodwillAndIntangibleAssets | 0 | 0 | 0 |
| longTermInvestments | 0 | 0 | 0 |
| taxAssets | 0 | 0 | 0 |
| otherNonCurrentAssets | 0 | 0 | 0 |
| totalNonCurrentAssets | 124,769 | 18,987 | 18,987 |
| otherAssets | 0 | 0 | 0 |
| totalAssets | 442,113 | 2,269,035 | 2,269,035 |
| accountPayables | 1,145,942 | 378,011 | 378,011 |
| shortTermDebt | 2,083,223 | 2,028,154 | 2,028,154 |
| taxPayables | 0 | 0 | 0 |
| deferredRevenue | 0 | 0 | 235,193 |
| otherCurrentLiabilities | 231,006 | 237,459 | 237,459 |
| totalCurrentLiabilities | 3,460,171 | 2,643,624 | 2,643,624 |
| longTermDebt | 55,701 | 0 | 0 |
| deferredRevenueNonCurrent | 0 | 0 | 0 |
| deferrredTaxLiabilitiesNonCurrent | 0 | 0 | 0 |
| otherNonCurrentLiabilities | 0 | 0 | 0 |
| totalNonCurrentLiabilities | 55,701 | 0 | 0 |
| otherLiabilities | 0 | 0 | 0 |
| totalLiabilities | 3,515,872 | 2,643,624 | 2,643,624 |
| preferredStock | 0 | 0 | 0 |
| commonStock | 13,353,439 | 11,278,117 | 11,278,117 |
| retainedEarnings | -18,092,050 | -13,979,997 | -13,979,997 |
| accumulatedOtherComprehensiveIncomeLoss | -822 | 2,327,291 | 2,327,291 |
| othertotalStockholdersEquity | 1,665,674 | 0 | 0 |
| totalStockholdersEquity | -3,073,759 | -374,589 | -374,589 |
| totalLiabilitiesAndStockholdersEquity | 442,113 | 2,269,035 | 2,269,035 |
| totalInvestments | 28,750 | 0 | 0 |
| totalDebt | 2,138,924 | 2,028,154 | 2,028,154 |
| netDebt | 1,973,239 | 171,581 | 171,581 |
| link | |||
| finalLink | |||
| minorityInterest | 0 | 0 | 0 |
| capitalLeaseObligations | 88,924 | 0 | 0 |
| totalEquity | -3,073,759 | -374,589 | -374,589 |
Izotropic Corporation
Description: Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Website:https://izocorp.com
Industry: Medical - Diagnostics & Research
Sector: Healthcare
CEO:
Full-Time Employees:
Address: 800 – 15355 24th Avenue, Surrey, BC, V4A 2H9, CA
Phone: 833 496 2677
Currency: USD
CIK:
ISIN: CA46604F1099
CUSIP:
Exchange: Other OTC
Exchange Short Name: PNK
IPO Date: 2021-01-08
| Ticker | peRatio | enterpriseValueOverEBITDA | evToFreeCashFlow | roic | netCurrentAssetValue | bookValuePerShare | priceToSalesRatio | netIncomePerShare |
|---|---|---|---|---|---|---|---|---|
| IZOZF | -3.79 | -4.97 | 0.88 | -3,912,404.00 | -0.07 | 0.00 | -0.03 | |
| IVRO | 838.98 | 148.17 | -0.01 | 1,388,183.00 | 0.06 | 1.64 | 0.00 | |
| BDSX | -2.90 | -5.00 | -0.63 | -54,833,000.00 | 0.06 | 3.08 | -0.64 | |
| STIM | -2.75 | -3.77 | -0.31 | 12,152,000.00 | 1.19 | 1.16 | -1.05 | |
| STRR | 0.65 | -0.97 | -0.05 | 24,609,000.00 | 20.88 | 0.36 | 8.04 | |
| GTH | ||||||||
| PMD | -4.09 | -69.02 | -0.39 | 1,151,000.00 | 1.16 | 0.77 | -0.72 | |
| SERA | -5.15 | -5.23 | -0.55 | 36,061,000.00 | 2.25 | 609.74 | -1.16 | |
| OLK | -98.51 | -97.86 | -0.07 | 163,916,107.00 | 4.05 | 18.35 | -0.26 | |
| DRIO | -0.82 | -0.76 | -0.64 | 9,085,000.00 | 2.05 | 2.40 | -2.09 | |
| RSHN | -2.83 | -10.60 | -0.11 | -5,757,902.00 | 0.00 | 0.96 | 0.00 | |
| APDN | -79.53 | -81.86 | -0.97 | -652,595.00 | 7.45 | 59.18 | -15.21 | |
| AKU | ||||||||
| RDNT | 726.24 | 11.47 | 0.03 | -1,297,838,000.00 | 12.79 | 1.37 | 0.05 | |
| STRRP | 0.65 | -0.97 | -0.05 | 24,609,000.00 | 20.88 | 0.36 | 8.04 | |
| LAB | -2.34 | -4.07 | -0.28 | -1,650,000.00 | 2.06 | 1.65 | -0.94 | |
| NDRA | -3,332.68 | -3,426.24 | -1.74 | 1,937,655.00 | 0.63 | 0.00 | -1.11 |
Analyst Estimates
Latest News
Izotropic Provides Marketing Update
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 13, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into an agreement with 1822053 Alberta Ltd. (d/b/a Evolux Capital) ("Evolux") to provide marketing services to the Company.
Izotropic Revises License Agreement with The Regents of the University of California
- License agreement enables U.S. FDA approval or foreign equivalent (CE mark) - - Amendment aligns with Company's timelines for IzoView product launch - - Agreement amendment fees of USD $85K payable in installments - Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - June 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that it has revised its exclusive global licensing agreement with the Regents of the University of California ("UC Davis") to align with the Company's current strategic positioning, regulatory pathway, and global commercialization plans for the IzoView Breast CT Imaging System ("IzoView"), and other planned imaging-based products. Izotropic holds the exclusive worldwide licensing rights to Breast CT and other technologies, patents, and patent applications developed at UC Davis Medical Center, in Sacramento, California.
Izotropic's U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
- Regulatory alignment with FDA confirmed, clearing path to pivotal U.S. clinical trial - - 150-page strategic business plan and advanced financial models completed - - Investor outreach launched to fund clinical execution and market entry - Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - May 16, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that further to its March 25th press release, it has confirmed alignment with the U.S. Food and Drug Administration ("FDA") on its regulatory strategy for the IzoView Breast CT Imaging System, ("IzoView"), finalized an updated business plan and financial model, and is now actively engaged in financing meetings to support its planned U.S.-based clinical study for market authorization. In March 2025, the Company held a pre-submission meeting with the FDA to review its proposed regulatory pathway for IzoView.
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 2, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has engaged an International Communications Consultant, and granted Incentive Stock Options and Restricted Share Units to Directors, Advisors, and Key Consultants. International Communications Consultant Izotropic has engaged JG Global Communications, led by Mr.
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
- FDA meeting facilitated positive collaborative exchange - - Key topics included the clinical study protocol synopsis, the benefits versus risks of contrast-enhancement, and the management of breast cancers found on IzoView Breast CT that are not visible on digital breast tomosynthesis - - Izotropic to submit meeting minutes to the FDA prior to more detailed disclosure - Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 25, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that it completed its pre-submission meeting with the U.S. Food and Drug Administration ("FDA") as scheduled on March 20, 2025. The purpose of the meeting was to discuss Izotropic's recent pre-submission filing and advance the regulatory strategy for its IzoView Breast CT Imaging System.
Izotropic to Present at Investor Conference March 13th
- CEO to discuss IzoView's competitive advantage, expansion strategy, and potential revenue models - - Event includes live Q and A, attendance is complimentary - - Individual and institutional investors, advisors, and analysts welcome - Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - March 10, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that CEO Robert Thast will be presenting at the Life Sciences Virtual Investor Conference this week, where he will highlight the transformative potential of the Company's first medical imaging device, the IzoView Breast CT system, in the expanding breast imaging market. Date: March 13th, 2025 Time: 11:00 - 11:30am PST / 2:00 - 2:30pm EST Book a 1 x 1 Meeting: See availability here: https://calendly.com/izotropic/meeting-with-ceo The global breast imaging device market is expected to surge from $5.40 billion in 2024 to $8.69 billion by 2030, driven by rising breast cancer incidence rates, aging populations, and expanding adoption in emerging markets.
